FDA Approves Replimune's Melanoma Drug Tudriqev on Third Attempt

Replimune Group received accelerated approval from the U.S. Food and Drug Administration (FDA) for its melanoma treatment Tudriqev on Thursday, marking the end of a regulatory saga that included three submissions and two prior rejections. The approval was granted under the FDA's accelerated approval pathway, which allows earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on a surrogate endpoint that is reasonably likely to predict clinical benefit. Tudriqev is an oncolytic immunotherapy designed to selectively replicate in tumor cells and trigger an immune response. The drug's approval is significant for Replimune, a biotechnology company focused on developing novel therapies for cancer, as it represents the company's first FDA-approved product. The decision follows a review of data from clinical trials that demonstrated the drug's efficacy in treating certain patients with melanoma, a form of skin cancer that can be deadly if not caught early. The approval also highlights the FDA's willingness to work with developers to bring innovative treatments to patients, even after initial setbacks. Replimune's stock rose in response to the news, reflecting investor optimism about the drug's commercial potential. The company plans to launch Tudriqev in the coming months, with a focus on making it accessible to patients who have limited treatment options.